UNLABELLED: We report on a male infant presenting at 4 months of age with failure to thrive, dehydration, hypotonia, lethargy, and vomiting. Laboratory and imaging tests revealed severe hypercalcemia (5.8 mmol/l), suppressed parathyroid hormone (0.41 pmol/l), hypercalciuria (8.0 mmol/mmol creatinine), elevated 25-hydroxyvitamin D3 (over 600 nmol/l), and nephrocalcinosis. These symptoms are characteristic of idiopathic infantile hypercalcemia (IIH, MIM 143880). Conservative therapy (parenteral rehydration, diuretics, corticosteroids, bisphosphonates, and vitamin D prophylaxis withdrawal) was not able to improve the symptoms and laboratory values, and acute hemodiafiltration was necessary to normalize hypercalcemia. Clinical symptoms resolved rapidly after normalization of serum calcium levels. Molecular genetic testing revealed a homozygous mutation (R396W) in the CYP24A1 gene (MIM 126065) encoding 25-hydroxyvitamin D3 24-hydroxylase, which is the key enzyme responsible for 1,25-dihydroxyvitamin D3 degradation. The CYP24A1 gene mutation leads to the increased sensitivity of the patients to even prophylactic doses of vitamin D and to the development of severe symptomatic hypercalcemia in patients with IIH. CONCLUSION: Our patient is only the thirteenth patient with IIH caused by mutation in the CYP24A1 gene and the first one needing acute hemodiafiltration for severe symptomatic hypercalcemic crisis. In all patients with suspected IIH the DNA analysis for CYP24A1 gene mutations should be performed regardless of the type of vitamin D supplementation and serum levels of vitamin D.

Department of Paediatrics 2nd Faculty of Medicine Charles University Prague Prague Czech Republic

See more in PubMed

J Clin Endocrinol Metab. 2012 Feb;97(2):E268-74 PubMed

Pediatr Nephrol. 1997 Feb;11(1):2-6 PubMed

Biophys J. 2006 May 15;90(10):3389-409 PubMed

Schweiz Med Wochenschr. 1951 Sep 22;81(38):908-13 PubMed

Kinderarztl Prax. 1985 Aug;53(8):383-93 PubMed

N Engl J Med. 2011 Aug 4;365(5):410-21 PubMed

Trends Biochem Sci. 2004 Dec;29(12):664-73 PubMed

Endocrinology. 2005 Feb;146(2):825-34 PubMed

Pediatr Nephrol. 2006 Nov;21(11):1676-80 PubMed

Kinderarztl Prax. 1986 Aug;54(8):431-8 PubMed

N Engl J Med. 2011 Nov 3;365(18):1741-2; author reply 1742-3 PubMed

N Engl J Med. 2011 Nov 3;365(18):1741; author reply 1742-3 PubMed

Annu Rev Biochem. 1976;45:631-66 PubMed

Arch Biochem Biophys. 2012 Jul 1;523(1):9-18 PubMed

Lancet. 1953 Aug 1;265(6779):255-6 PubMed

Pediatrics. 1967 Dec;40(6):1050-61 PubMed

J Clin Endocrinol Metab. 2012 Mar;97(3):E423-7 PubMed

Am J Clin Nutr. 2008 Aug;88(2):582S-586S PubMed

Case report: Two heterozygous pathogenic variants of CYP24A1: A novel cause of hypercalcemia and nephrocalcinosis in adulthood